Actuate Therapeutics
Manufacturing · Texas, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1751 River Run Ste 400, Fort Worth, Texa...Phone Number
(817) 887-8455Website
www.actuatetherapeutics.comRevenue
<$5 MillionStock Symbol
ACTUIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
1
1
1
1
1
About Actuate Therapeutics
Actuate is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics for cancers and inflammatory diseases. In addition to this randomized controlled study, Actuate is executing Phase 2 clinical trial for the treatment of myelofibrosis, a Phase 1/2 trial for neuroblastoma in pediatric patients, and a Phase 2 trial in salivary gland carcinomas. The company is also planning additional clinical studies of elraglusib in other cancers including studies for front line treatment of advanced pancreatic cancer both in combination with FOLFIRINOX, and with a checkpoint inhibitor containing regimen.Explore more
Actuate Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Actuate Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Actuate Therapeutics launches new products
Earning: See what the market has to say on Actuate Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Actuate Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Actuate Therapeutics
Click to see if Actuate Therapeutics had a recent Job posting/layoffs
Check out if Actuate Therapeutics is spiking on competitors!
Actuate Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Actuate Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Actuate Therapeutics
Find more new buyers
Compare Similar Companies to Actuate Therapeutics
Compare insights from companies similar to Actuate Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Actuate Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Actuate Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Actuate Therapeutics.
Actuate Therapeutics financials insights
Gather financial insights about Actuate Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Private Equity
$3M
2018
Series A
$7M
2019
Series B
$28.2M
2025
Private Equity
$4.7M
Actuate Therapeutics Tech Stack
A closer look at the technologies used by Actuate Therapeutics
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Actuate Therapeutics has reported that Elverglucib demonstrates minimal clinical risk with only two safety signals: temporary visual impairment (color blindness in the red spectrum lasting one hour to 24 hours post-infusion) and increased grade 3-4 neutropenia, both manageable with no intervention required for the visual effects.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Actuate Therapeutics has reported that Phase 2 trial demonstrated that patients completing at least one full cycle of Elverglucib plus gemcitabine achieved median overall survival of approximately 11 months compared to 7.2 months for gemcitabine alone, representing a hazard ratio of 0.5 and a 42% reduction in risk of death with nearly doubled one-year overall survival.
Medical Research, Pharmaceuticals, Clinical Operations, Finance, Risk
Project
Actuate Therapeutics has reported that lead compound Elverglucib has been credentialed preclinically in 18 different histologies across laboratories worldwide, with results published in scientific literature.
Medical Research, Pharmaceuticals
Project
Medical Research, Clinical Operations
Actuate Therapeutics News & Media
Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer
- Patients with KRAS wild-type (WT) genomics achieved significant improvement in median overall survival (mOS) when treated with elraglusib plus gemcitabine/Abraxane (GnP) versus GnP aloneActuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program
CHICAGO and FORT WORTH, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers, today announced key initiatives to advance and expand the potential of the elraglusib development program.Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors
Martin Huber, MD brings deep expertise in oncology drug development, regulatory strategy, and commercialization of novel therapies Martin Huber, MD brings deep expertise in oncology drug development, regulatory strategy, and commercialization of novel therapiesActuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
CHICAGO and FORT WORTH, Texas, April 14, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced the publication of new data in Nature Medicine from a randomized phase 2 clinical trial (NCT03678883) evaluating elraglusib in combination wit
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Actuate Therapeutics
Sign Up For FreeTo access detailed company insights
Actuate is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics for cancers and inflammatory diseases. In addition to this randomized controlled study, Actuate is executing Phase 2 clinical trial for the treatment of myelofibrosis, a Phase 1/2 trial for neuroblastoma in pediatric patients, a... Read More
